🔎 Trials Near Me

Beranda › Kanker Kolon › Illinois

Uji klinis Kanker Kolon di Illinois

18 studi untuk Kanker Kolon mencari peserta di lokasi di Illinois.

Kota di Illinois

Teks studi resmi (Bahasa Inggris)

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

  • OSF Saint Anthony's Health Center, Alton
  • Illinois CancerCare-Bloomington, Bloomington
  • Illinois CancerCare-Canton, Canton
  • dan 31 lainnya
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07283939

Family Communications After Genetic Testing

  • OSF Saint Anthony's Health Center, Alton
  • Advocate Outpatient Center - Aurora, Aurora
  • Advocate Good Shepherd Hospital, Barrington
  • dan 46 lainnya
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07143487

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  • Endeavor Health ( Site 2027), Evanston
  • Accellacare of Duly ( Site 2015), Lisle
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06997497

PRE-ISPY Phase I/II Oncology Platform Program

  • The University of Chicago Medicine Comprehensive Cancer Center, Chicago
  • UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
  • UChicago Medicine Orland Park, Orland Park
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05868226

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  • Illinois Cancer Specialists, Arlington Heights
  • Illinois CancerCare - Bloomington, Bloomington
  • Illinois Cancer Specialists, Chicago
  • dan 10 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07222800

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  • Sih Cancer Institute, Carterville
  • University of Illinois Cancer Center, Chicago
  • Alexian Brothers Medical Center, Elk Grove Village
  • dan 2 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07284849

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

  • OSF Saint Anthony's Health Center, Alton
  • John H Stroger Jr Hospital of Cook County, Chicago
  • Loyola University Medical Center, Maywood
  • dan 3 lainnya
Menerima peserta
Usia 45 hingga 70 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT05080673

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  • OSF Saint Anthony's Health Center, Alton
  • Rush-Copley Medical Center, Aurora
  • Advocate Outpatient Center - Aurora, Aurora
  • dan 73 lainnya
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT05174169

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

  • Northwestern University, Chicago
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT07594626

Shield Post-Approval Study Protocol

  • Digestive Disease Consultants, Bourbonnais
  • Digestive Disease Consultants, Bourbonnais
  • Christie Clinic, Champaign
  • dan 9 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 45 hingga 81 · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT06880055

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Chicago
  • Xencor Investigative Site, Chicago
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT05433142

Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

  • City of Hope at Illinois Chicago Downtown, Chicago
  • City of Hope at Chicago, Zion
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Jul 2026 · NCT07595874

Integrated Cancer Repository for Cancer Research

  • Rush-Copley Cancer Care Center, Aurora
  • Rush-Copley Healthcare Center, Yorkville
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

  • Illinois Cancer Specialists, Arlington Heights
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT07011576

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

  • University of Chicago, Chicago
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

  • Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine University of Chicago Medicine, Chicago
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 49 · Semua jenis kelamin · Diperbarui 24 Apr 2026 · NCT05732623

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  • GSK Investigational Site, Chicago
  • GSK Investigational Site, Chicago
  • GSK Investigational Site, Naperville
  • dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jan 2026 · NCT05855200

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Chicago
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.